EP0835320A1 - Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie - Google Patents

Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie

Info

Publication number
EP0835320A1
EP0835320A1 EP96915215A EP96915215A EP0835320A1 EP 0835320 A1 EP0835320 A1 EP 0835320A1 EP 96915215 A EP96915215 A EP 96915215A EP 96915215 A EP96915215 A EP 96915215A EP 0835320 A1 EP0835320 A1 EP 0835320A1
Authority
EP
European Patent Office
Prior art keywords
gene
cells
vector
vector according
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96915215A
Other languages
English (en)
French (fr)
Inventor
Ronald Vogels
Johannes Jozephes Bernardus Boesen
Helmuth Hendrikus Gerardus Van Es
Victor Willem Van Beusechem
Domenico Valerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgene BV
Original Assignee
Introgene BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene BV filed Critical Introgene BV
Priority to EP96915215A priority Critical patent/EP0835320A1/de
Publication of EP0835320A1 publication Critical patent/EP0835320A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96915215A 1995-05-10 1996-05-07 Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie Withdrawn EP0835320A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96915215A EP0835320A1 (de) 1995-05-10 1996-05-07 Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP95201211 1995-05-10
EP95201211 1995-05-10
PCT/NL1996/000195 WO1996035798A1 (en) 1995-05-10 1996-05-07 Improved retroviral vectors, especially suitable for gene therapy
EP96915215A EP0835320A1 (de) 1995-05-10 1996-05-07 Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie

Publications (1)

Publication Number Publication Date
EP0835320A1 true EP0835320A1 (de) 1998-04-15

Family

ID=8220283

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96915215A Withdrawn EP0835320A1 (de) 1995-05-10 1996-05-07 Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie

Country Status (5)

Country Link
EP (1) EP0835320A1 (de)
JP (1) JPH11511651A (de)
AU (1) AU5703796A (de)
CA (1) CA2218808A1 (de)
WO (1) WO1996035798A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288328A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2001002551A2 (en) * 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
JPWO2008108344A1 (ja) * 2007-03-02 2010-06-17 セルジェンテック株式会社 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959313A (en) * 1987-06-22 1990-09-25 The Jackson Laboratory Cellular enhancer for expressing genes in undifferentiated stem cells
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
WO1994029437A1 (en) * 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5631162A (en) * 1993-06-11 1997-05-20 Massachusetts Institute Of Technology Retroviral vectors for transducing β-globin gene and β-locus control region derivatives
US5707865A (en) * 1994-12-21 1998-01-13 Kohn; Donald B. Retroviral vectors for expression in embryonic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9635798A1 *

Also Published As

Publication number Publication date
CA2218808A1 (en) 1996-11-14
WO1996035798A1 (en) 1996-11-14
JPH11511651A (ja) 1999-10-12
AU5703796A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
Vile et al. Retroviruses as vectors
US6312948B1 (en) Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
AU650085B2 (en) Bifunctional selectable fusion genes
JP4482578B2 (ja) 真核細胞にヌクレオチド配列を挿入し得る天然または合成のレトロエレメント配列
KR20000049250A (ko) 렌티바이러스 벡터
WO1994020608A1 (en) Improved vectors for gene therapy
US5858744A (en) Retroviral vector hybrids and the use thereof for gene transfer
US20110294873A1 (en) Gene Transfer Vectors Comprising At Least One Isolated DNA Molecule Having Insulator Or Boundary Properties And Methods To Identify The Same
US7056730B2 (en) Expression of heterologous genes from an IRES translational cassette in retroviral vectors
EP0835320A1 (de) Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie
US6190907B1 (en) Retroviral vectors for gene therapy
Haviernik et al. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors
METZ et al. Bicistronic and two-gene retroviral vectors for usingMDR1 as a selectable marker and a therapeutic gene
AU721326B2 (en) 10A1 retroviral packaging cells and uses thereof
Havenga et al. Methotrexate selectable retroviral vectors for Gaucher disease
Kaptein et al. Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo
IL116216A (en) Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
CA2199131C (en) Retroviral vector hybrids and the use thereof for gene transfer
US20020160971A1 (en) Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor
Roth Dual-gene transfer and vector targeting for hematopoietic stem cell gene therapy
Goodrich Construction of a novel self-inactivating gene activating vector: Splicing and non-encapsidation of vector RNA
WO2002064805A2 (en) Replication competent non-mammalian retroviral vectors
Logg Development of replication-competent retroviral vectors for efficient, targeted gene therapy of cancer
Zhang et al. MOLECULAR TARGETING OF CANCER: RETROVIRAL VECTOR-MEDIATED ANTISENSE NUCLEIC ACID THERAPY
Staplin Assessment of Vl30 Erythropoietin Responsive Promoters for Erthyroid Gene Therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 971113;LT PAYMENT 971113;LV PAYMENT 971113;SI PAYMENT 971113

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991201